[HTML][HTML] Characterization of JAK2 V617F allele burden in advanced myelofibrosis (MF) patients: no change in V617F: WT JAK2 ratio in patients with high allele …
S Verstovsek, HM Kantarjian, AD Pardanani, T Burn… - Blood, 2008 - Elsevier
Background: Activating mutations in the pseudokinase domain of JAK2 occur at a high
frequency in Philadelphia chromosome-negative myeloproliferative disorders (MPDs) …
frequency in Philadelphia chromosome-negative myeloproliferative disorders (MPDs) …
Characterization of JAK2 V617F Allele Burden in Advanced Myelofibrosis (MF) Patients: No Change in V617F: WT JAK2 Ratio in Patients with High Allele Burdens …
S Verstovsek, HM Kantarjian, AD Pardanani, T Burn… - Blood, 2008 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Background: Activating mutations in the
pseudokinase domain of JAK2 occur at a high frequency in Philadelphia chromosome …
pseudokinase domain of JAK2 occur at a high frequency in Philadelphia chromosome …
Characterization of JAK2 V617F Allele Burden in Advanced Myelofibrosis (MF) Patients: No Change in V617F: WT JAK2 Ratio in Patients with High Allele Burdens …
S Verstovsek, HM Kantarjian, AD Pardanani, T Burn… - 2008 - ashpublications.org
Background: Activating mutations in the pseudokinase domain of JAK2 occur at a high
frequency in Philadelphia chromosome-negative myeloproliferative disorders (MPDs) …
frequency in Philadelphia chromosome-negative myeloproliferative disorders (MPDs) …
[引用][C] Characterization of JAK2 V617F allele burden in advanced myelofibrosis (MF) patients: no change in V617F: WT JAK2 ratio in patients with high allele burdens …
S VERSTOVSEK - ASH annual meeting abstracts, 2008 - cir.nii.ac.jp
Characterization of JAK2 V617F allele burden in advanced myelofibrosis (MF) patients : no
change in V617F : WT JAK2 ratio in patients with high allele burdens despite profound clinical …
change in V617F : WT JAK2 ratio in patients with high allele burdens despite profound clinical …